<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(1)</volume><submitter>Umpierrez GE</submitter><pubmed_abstract>&lt;b>Background:&lt;/b> The association between falls or fall-related fractures and hypoglycemia in people with type 2 diabetes is well established. Insulin treatment is associated with an increased risk of hypoglycemia, which is compounded in people of older age, but the risk is lower with longer-acting vs intermediate- or long-acting basal insulin analogs. &lt;b>Objective:&lt;/b> To examine healthcare resource utilization and costs related to falls/fractures in people with type 2 diabetes treated with the longer-acting basal insulin Gla-300 (insulin glargine 300 U/mL) vs long-acting basal insulins (insulin glargine 100 U/mL or insulin detemir)/neutral protamine Hagedorn (NPH). &lt;b>Methods:&lt;/b> This retrospective study of Optum's de-identified Clinformatics® Data Mart Database compared data for peopl</pubmed_abstract><journal>Journal of health economics and outcomes research</journal><pagination>171-183</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12043012</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study.</pubmed_title><pmcid>PMC12043012</pmcid><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Preblick R</pubmed_authors><pubmed_authors>Pandya N</pubmed_authors><pubmed_authors>Umpierrez GE</pubmed_authors><pubmed_authors>Pogge EK</pubmed_authors><pubmed_authors>Gill J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study.</name><description>&lt;b>Background:&lt;/b> The association between falls or fall-related fractures and hypoglycemia in people with type 2 diabetes is well established. Insulin treatment is associated with an increased risk of hypoglycemia, which is compounded in people of older age, but the risk is lower with longer-acting vs intermediate- or long-acting basal insulin analogs. &lt;b>Objective:&lt;/b> To examine healthcare resource utilization and costs related to falls/fractures in people with type 2 diabetes treated with the longer-acting basal insulin Gla-300 (insulin glargine 300 U/mL) vs long-acting basal insulins (insulin glargine 100 U/mL or insulin detemir)/neutral protamine Hagedorn (NPH). &lt;b>Methods:&lt;/b> This retrospective study of Optum's de-identified Clinformatics® Data Mart Database compared data for peopl</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-03-13T10:32:57.762Z</modification><creation>2025-07-08T03:12:26.283Z</creation></dates><accession>S-EPMC12043012</accession><cross_references><pubmed>40309264</pubmed><doi>10.36469/001c.133274</doi></cross_references></HashMap>